Cytokinetics (CYTK) Return on Equity (2016 - 2025)
Cytokinetics (CYTK) has disclosed Return on Equity for 14 consecutive years, with 1.17% as the latest value for Q4 2025.
- Quarterly Return on Equity changed N/A to 1.17% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.17% through Dec 2025, changed N/A year-over-year, with the annual reading at 2.12% for FY2023, 718.0% up from the prior year.
- Return on Equity for Q4 2025 was 1.17% at Cytokinetics, down from 1.36% in the prior quarter.
- The five-year high for Return on Equity was 5.55% in Q4 2022, with the low at 11.85% in Q3 2024.
- Average Return on Equity over 5 years is 0.06%, with a median of 1.27% recorded in 2023.
- The sharpest move saw Return on Equity tumbled -1320bps in 2024, then surged 1321bps in 2025.
- Over 5 years, Return on Equity stood at 0.82% in 2021, then soared by 774bps to 5.55% in 2022, then tumbled by -77bps to 1.27% in 2023, then crashed by -1032bps to 11.85% in 2024, then skyrocketed by 110bps to 1.17% in 2025.
- According to Business Quant data, Return on Equity over the past three periods came in at 1.17%, 1.36%, and 1.8% for Q4 2025, Q3 2025, and Q2 2025 respectively.